RT Journal Article
SR Electronic
T1 Risk of Second Primary Cancers After a Diagnosis of First Primary Cancer: A Pan-Cancer Analysis and Mendelian Randomization Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.15.23285943
DO 10.1101/2023.02.15.23285943
A1 Ruan, Xiaohao
A1 Huang, Da
A1 Zhan, Yongle
A1 Huang, Jingyi
A1 Huang, Jinlun
A1 NG, Ada Tsui-Lin
A1 TSU, James Hok-Leung
A1 Na, Rong
YR 2023
UL http://medrxiv.org/content/early/2023/02/23/2023.02.15.23285943.abstract
AB Background The risk of second primary cancers (SPC) is increasing after the first primary cancers (FPC) are diagnosed and treated. The underlying causal relationship remains unclear.Methods We conducted a pan-cancer association (26 cancers) study in the Surveillance, Epidemiology, and End Results (SEER) database. The standardized incidence ratio (SIR) was estimated as the risk of SPCs in cancer survivors based on the incidence in the general population. Furthermore, the causal effect was evaluated by two-sample Mendelian Randomization (MR, 13 FPCs) in the UK Biobank (UKB, n=459,136) and robust analysis (radial MR and Causal Analysis Using Summary Effect estimates, CAUSE).Results We found 11 significant cross-correlations among different cancers after harmonizing SIR and MR results. Whereas only 4 of them were confirmed by MR to have a robust causal relationship. In particular, patients initially diagnosed with oral pharyngeal cancer would have an increased risk of non-Hodgkin lymphoma (SIRSEER=1.18, 95%Confidence Interval [CI]:1.05-1.31, ORradial-MR=1.21, 95%CI:1.13-1.30, P=6.00×10−3; ORcause=1.17, 95%CI:1.05-1.31, P=8.90×10−3). Meanwhile, ovary cancer was identified to be a risk factor for soft tissue cancer (SIRSEER=1.72, 95%Confidence Interval [CI]:1.08-2.60, ORradial-MR=1.39, 95%CI:1.22-1.58, P=1.07×10−3; ORcause=1.36, 95%CI:1.16-1.58, P=0.01). And kidney cancer was likely to cause the development of lung cancer (SIRSEER=1.28, 95%Confidence Interval [CI]:1.22-1.35, ORradial-MR=1.17, 95%CI:1.08-1.27, P=6.60×10−3; ORcause=1.16, 95%CI:1.02-1.31, P=0.05) and myeloma (SIRSEER=1.54, 95%Confidence Interval [CI]:1.33-1.78, ORradial-MR=1.24, 95%CI:1.21-2.45, P=0.02; ORcause=1.49, 95%CI:1.04-2.34, P=0.02).Conclusions A certain type of primary cancer may cause another second primary cancer, and the profound mechanisms need to be studied in the future.Funding This work was in supported by grants from National Natural Science Foundation of China (Grant No. 81972645), Innovative research team of high-level local universities in Shanghai, Shanghai Youth Talent Support Program, intramural grant of The University of Hong Kong to Dr. Rong Na, and Shanghai Sailing Program (22YF1440500) to Dr. Da Huang.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialN/AFunding StatementThis work was in supported by grants from National Natural Science Foundation of China (Grant No. 81972645), Innovative research team of high-level local universities in Shanghai, Shanghai Youth Talent Support Program, intramural grant of The University of Hong Kong to Dr. Rong Na, and Shanghai Sailing Program (22YF1440500) to Dr. Da Huang. All the funders had no role in study design, data collection, data analysis, interpretation, and writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Written informed consent was obtained from all the participants from SEER or UKB according to the established standard of the studies. The current study design was reviewed by the Institutional Review Board at Ruijin Hospital (Shanghai, China).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData used in this research are publicly available to qualified researchers on application to the SEER database (https://seer.cancer.gov/) and UK Biobank (www.ukbiobank.ac.uk).